Leading Indian fertility experts have cautioned against using non-invasive embryo genetic testing (niPGT) for routine clinical decisions. A joint review by ISAR, IFS, and ACE found the technique prone to high misdiagnosis rates, potentially leading to incorrect embryo selection or discarding. The technology, while promising, lacks sufficient evidence for clinical use.